University of Missouri-Columbia · Biomedical EngineeringNanoparticle Cancer Therapeutics Lab
Raghuraman Kannan · Columbia, Missouri
Research Focus
Dr. Raghuraman Kannan's lab at the University of Missouri-Columbia focuses on developing innovative nanoparticle technologies to treat drug-resistant non-small cell lung cancer (NSCLC). The team aims to create targeted nanoparticles that can knock down specific proteins responsible for cancer cell survival, overcoming resistance to traditional therapies. Their research combines engineering, biology, and clinical relevance, working towards future therapeutic strategies to improve patient outcomes.
nanoparticlesnon-small cell lung cancerdrug resistancetyrosine kinase inhibitorsimmunotherapysiRNAcancer therapyclinical trialsmolecular targeting
Research Aims
5AIM 01Design targeted nanoparticles to co-knockdown multiple proteins in NSCLC
AIM 02Evaluate the safety and efficacy of MU-CN29 in relevant animal models
AIM 03Optimize nanoparticle size for better tumor penetration
AIM 04Develop protocols for clinical-grade production of nanoparticles
AIM 05Investigate the potential of the nanoparticles to restore drug sensitivity in resistant tumors.
Skills the Lab Values
nanoparticle synthesiscell culture techniquesanimal models (murine and canine)siRNA technologypharmacokineticstumor biodistribution studiesimmunohistochemistrypatient-derived xenograftsdata analysis using Python
Output against the department
Publications146bottom 31% of dept.408th of 595
this lab
most publishedleast published
Citations4.3kbottom 33% of dept.398th of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.